These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15661266)

  • 1. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.
    Schirrmann T; Pecher G
    Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
    Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
    Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
    Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
    Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells.
    Falco M; Marcenaro E; Romeo E; Bellora F; Marras D; Vély F; Ferracci G; Moretta L; Moretta A; Bottino C
    Eur J Immunol; 2004 Jun; 34(6):1663-72. PubMed ID: 15162436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing.
    Hernández-Caselles T; Martínez-Esparza M; Pérez-Oliva AB; Quintanilla-Cecconi AM; García-Alonso A; Alvarez-López DM; García-Peñarrubia P
    J Leukoc Biol; 2006 Jan; 79(1):46-58. PubMed ID: 16380601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
    Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
    J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of an anti-CD33 single-chain antibody by Pichia pastoris.
    Emberson LM; Trivett AJ; Blower PJ; Nicholls PJ
    J Immunol Methods; 2005 Oct; 305(2):135-51. PubMed ID: 16139294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.
    Chin LT; Chu C; Chen HM; Hsu SC; Weng BC; Chu CH
    BMC Biotechnol; 2007 Aug; 7():51. PubMed ID: 17714596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
    Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
    Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy.
    Gupta N; Arthos J; Khazanie P; Steenbeke TD; Censoplano NM; Chung EA; Cruz CC; Chaikin MA; Daucher M; Kottilil S; Mavilio D; Schuck P; Sun PD; Rabin RL; Radaev S; Van Ryk D; Cicala C; Fauci AS
    Virology; 2005 Feb; 332(2):491-7. PubMed ID: 15680414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction, expression and functional characterization of single chain variable fragments (scFv) against human CD33 antigen].
    Chen XJ; Wang Y; Qu H; Ge XS; Zuo YF; Liao XL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1147-9. PubMed ID: 18062889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
    Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
    Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.
    Myers KA; Ryan MG; Stern PL; Shaw DM; Embleton MJ; Kingsman SM; Carroll MW
    Cancer Gene Ther; 2002 Nov; 9(11):884-96. PubMed ID: 12386827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.
    Germain C; Larbouret C; Cesson V; Donda A; Held W; Mach JP; Pèlegrin A; Robert B
    Clin Cancer Res; 2005 Oct; 11(20):7516-22. PubMed ID: 16243826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric and humanized antibodies with specificity for the CD33 antigen.
    Co MS; Avdalovic NM; Caron PC; Avdalovic MV; Scheinberg DA; Queen C
    J Immunol; 1992 Feb; 148(4):1149-54. PubMed ID: 1737932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and characterization of a single-gene mouse-human chimeric antibody against hepatitis B surface antigen.
    Bose B; Khanna N; Acharya SK; Sinha S
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1439-47. PubMed ID: 16911690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.